The COVID-19 pandemic has posed significant challenges, particularly for individuals with pre-existing conditions like hypertension. A recent study by researchers at the Pontifical Catholic University of Rio Grande do Sul (PUCRS) in Brazil has shed light on the potential impact of two common antihypertensive medications, losartan and enalapril maleate, on SARS-CoV-2-infected cells. The findings reveal intriguing insights into how these drugs may differentially influence the virus’s replication and the host cell’s response, providing valuable information for understanding the complex interplay between COVID-19 and pre-existing medical conditions.
Unraveling the Mysteries of SARS-CoV-2 Infection
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been a global health crisis, claiming over 7 million lives worldwide. While numerous treatments have been tested or are still under investigation, a highly specific and definitive therapeutic solution remains elusive, posing a significant challenge for healthcare systems globally.
Notably, individuals with pre-existing conditions, such as hypertension, are at a higher risk of SARS-CoV-2 infection and developing severe complications, including acute respiratory distress syndrome (ARDS), organ damage, and secondary infections. This observation has raised concerns about the potential impact of common antihypertensive medications, such as angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEis), on the course of COVID-19.
Investigating the Differential Effects of Losartan and Enalapril Maleate
The study conducted by the researchers at PUCRS aimed to assess the impact of the ARB losartan and the ACEi enalapril maleate on SARS-CoV-2-infected cells. They utilized the Click Here
![Click Here](https://en.wikipedia.org/wiki/Vero<em>cell’>Vero E6 cell line</a>, a widely used model for SARS-CoV-2 replication, to investigate the effects of these antihypertensive drugs on virus infection, cell viability, and the expression of key cellular genes.</p>
<p><figure class="wp-block-image size-large"><img decoding="async" src="https://famefreq.s3.us-east-2.amazonaws.com/1729769048_41598_2024_76657_Fig1_HTML.png" alt="figure 1" class="wp-image-1" /><figcaption class="wp-element-caption">Fig. 1</figcaption></figure>
</p>
<p><h3>Losartan Significantly Reduces Viral RNA Levels</h3>
<p>The researchers found that both losartan and enalapril maleate were non-toxic to the Vero E6 cells, even at the highest concentrations tested. However, the two drugs exhibited distinct effects on SARS-CoV-2 infection. Notably, losartan at the highest concentration (1000 μM) substantially reduced the levels of the viral <b>nucleocapsid RNA</b> to near-undetectable levels, while enalapril maleate did not demonstrate a significant effect on viral replication.</p>
<p><figure class="wp-block-image size-large"><img decoding="async" src="https://famefreq.s3.us-east-2.amazonaws.com/1729769050_41598_2024_76657_Fig2_HTML.png" alt="figure 2" class="wp-image-2" /><figcaption class="wp-element-caption">Fig. 2</figcaption></figure>
</p>
<p><h3>Differential Modulation of Cellular Pathways</h3>
<p>The study also investigated the influence of these antihypertensive drugs on the expression of key cellular genes, including <b>interleukin-6 (IL-6)</b>, <b>interleukin-18 (IL-18)</b>, <b>p53</b>, <b>p21</b>, and <b>p62</b>. These genes are known to play crucial roles in cellular processes, such as inflammation, cell cycle regulation, and autophagy, which are often disrupted by SARS-CoV-2 infection.</p>
<p>The findings revealed distinct profiles in the expression of these genes when comparing infected cells treated with losartan or enalapril maleate. For instance, while both treatments led to an upregulation of IL-6 expression in infected cells, only enalapril maleate-treated cells showed a significant increase in IL-18 levels. Furthermore, infected cells treated with enalapril maleate exhibited higher expression of p53 and p21, suggesting a potential influence on cell cycle regulation and DNA damage response pathways.</p>
<p><figure class="wp-block-image size-large"><img decoding="async" src="https://famefreq.s3.us-east-2.amazonaws.com/1729769052_41598_2024_76657_Fig3_HTML.png" alt="figure 3" class="wp-image-3" /><figcaption class="wp-element-caption">Fig. 3</figcaption></figure>
</p>
<p><h3>Potential Implications and Future Directions</h3>
<p>The data from this study suggest that losartan and enalapril maleate can differentially interfere with the effects triggered by SARS-CoV-2 infection in Vero E6 cells. Losartan’s ability to substantially reduce viral RNA levels, coupled with its modulation of cellular pathways, indicates that this ARB may have a more direct antiviral impact compared to enalapril maleate.</p>
<p>These findings have several important implications:</p>
<ul>
<li>They provide insights into the potential mechanisms by which antihypertensive medications may influence the course of COVID-19, particularly in individuals with pre-existing hypertension.</li>
<li>The distinct profiles observed in the expression of key cellular genes suggest that losartan and enalapril maleate may differentially modulate the host cell’s response to SARS-CoV-2 infection.</li>
<li>The data highlight the need for further investigation into the specific signaling pathways and cellular processes impacted by these antihypertensive drugs, which may lead to the identification of novel therapeutic targets or strategies for COVID-19 management.</li>
</ul>
<p><figure class="wp-block-image size-large"><img decoding="async" src="https://famefreq.s3.us-east-2.amazonaws.com/1729769054_41598_2024_76657_Fig4_HTML.png" alt="figure 4" class="wp-image-4" /><figcaption class="wp-element-caption">Fig. 4</figcaption></figure>
</p>
<p><h3>Unraveling the Complex Interplay</h3>
<p>The study by the researchers at PUCRS represents an important step in unraveling the complex interplay between antihypertensive medications, SARS-CoV-2 infection, and the host cell’s response. By elucidating the differential effects of losartan and enalapril maleate, this research contributes to our understanding of how pre-existing medical conditions and their treatments may influence the course of COVID-19. As the scientific community continues to explore effective therapies and management strategies for this global health challenge, studies like this one will be instrumental in guiding future research and informing clinical decision-making.</p>
<p>Meta description: Researchers uncover the differential impact of antihypertensive drugs, losartan and enalapril maleate, on SARS-CoV-2 infection and host cell response, providing valuable insights for COVID-19 management.</p>
<hr />
<p>For More Related Articles <a href=){kind=link}